Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus disease 2019 (COVID-19). This study has assessed a new Anti-SARS-COV-2 mAb (SA58) Nasal Spray for PEP against COVID-19 in healthy adults aged 18 years...

Full description

Bibliographic Details
Main Authors: Rui Song, Gang Zeng, Jianxing Yu, Xing Meng, Xiaoyou Chen, Jing Li, Xiaoliang Xie, Xiaojuan Lian, Zhiyun Zhang, Yunlong Cao, Weidong Yin, Ronghua Jin
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Monoclonal antibodies
Post-exposure prophylaxis
SARS-CoV-2
COVID-19
Clinical trial
China
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2212806

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2023.2212806

Similar Items